Poland

Ryvu Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

POLAND Poland

Post An Enquiry

Virtual Booth

Natural Products Expo

Participation Not Confirmed

Update your events

Ryvu Therapeutics to Receive NCRD Grant to Develop Targeted Immuno-Oncology Therapy

Lead Product(s): SEL120

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: National Centre for Research and Development

Deal Size: $8.9 million Upfront Cash: Undisclosed

Deal Type: Agreement June 05, 2020

Details:

This grant Supports Ryvu to develop and select a clinical candidate targeting cancers which had been considered in the past as largely undruggable using rational approaches.

Ryvu Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

POLAND Poland

Post An Enquiry

Virtual Booth

Natural Products Expo

Participation Not Confirmed

Update your events

Ryvu Therapeutics Receives Orphan Drug Designation From FDA for SEL120 to Treat Acute Myeloid Leukemia

Lead Product(s): SEL120

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 28, 2020

Details:

SEL120 has shown strong proof of concept in the preclinical studies and has received a strategic support from The Leukemia & Lymphoma Society (LLS) through its Therapy Acceleration Program.

WPD Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

POLAND Poland

Post An Enquiry

Virtual Booth

Natural Products Expo

Participation Not Confirmed

Update your events

WPD Pharmaceuticals' STAT3 Inhibitor Received FDA Approval of IND Status in Pediatric Brain Cancer Trial

Lead Product(s): WP1066

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 20, 2020

Details:

WP1066 drug candidate received FDA approval for Investigational New Drug status to be used in a Phase 1 clinical trial for recurrent or refractory malignant brain tumors in children.

Find

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Product Type

Companies

Ryvu Therapeutics

Ryvu Therapeutics to Receive NCRD Grant to Develop Targeted Immuno-Oncology Therapy

Ryvu Therapeutics

Ryvu Therapeutics Receives Orphan Drug Designation From FDA for SEL120 to Treat Acute Myeloid Leukemia

WPD Pharmaceuticals

WPD Pharmaceuticals' STAT3 Inhibitor Received FDA Approval of IND Status in Pediatric Brain Cancer Trial